Research Papers:

Prognostic role of podocalyxin-like protein expression in various cancers: A systematic review and meta-analysis

Jing Wang _, Yongzhao Zhao, Ruizhao Qi, Xiaoning Zhu, Chenshen Huang, Sijin Cheng, Shengzhi Wang and Xiaolong Qi

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:52457-52464. https://doi.org/10.18632/oncotarget.14199

Metrics: PDF 1165 views  |   HTML 1479 views  |   ?  


Jing Wang1,*, Yongzhao Zhao2,*, Ruizhao Qi3,*, Xiaoning Zhu1, Chenshen Huang2, Sijin Cheng2, Shengzhi Wang3 and Xiaolong Qi1

1Department of Hepatobiliary Disease, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China

2School of Medicine, Tongji University, Shanghai, China

3Department of General Surgery, 302 Hospital of PLA, Beijing, China

*These authors have contributed equally to this work

Correspondence to:

Yongzhao Zhao, email: yongzhao_zhao@163.com

Shengzhi Wang, email: 994233529@qq.com

Keywords: prognostic, podocalyxin-like protein, cancer, overall survival

Received: October 19, 2016    Accepted: November 20, 2016    Published: December 25, 2016


Several studies were conducted to explore the prognostic significance of podocalyxin-like protein (PODXL) expression in various cancers, with contradictory. This study aims to summarize the prognostic significance of PODXL expression in cancers. PubMed, the Cochrane Library and Embase were completely retrieved. The prospective or retrospective studies focusing on the prognostic role of PODXL expression in cancers were eligible. The endpoints were overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS).12 studies involving a total of 5,309 patients were identified. The results indicated that high PODXL expression was significantly associated with worse OS when compared to the low PODXL expression (HR=1.76, 95%CI=1.53-2.04, p<0.00001; I2=41%, p=0.08). And similar results were detected in the subgroup analysis of analysis model, ethnicity, sample size, tumor type and antibody type. And the results also showed that high PODXL expression was obviously related to shorter DSS (HR=2.47, 95%CI=1.53-3.99, p=0.0002; I2=66%, p=0.03) and DFS (HR=2.12, 95%CI=1.58-2.85, p<0.00001; I2=19%, p=0.29). In conclusion, it was revealed that high PODXL expression is an unfavorable predictor of OS, DSS and DFS in patients with cancers, and high PODXL expression is a promising prognostic biomarker for cancers, especially for patients in European.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14199